A detailed history of Visionary Wealth Advisors transactions in Biocryst Pharmaceuticals Inc stock. As of the latest transaction made, Visionary Wealth Advisors holds 27,790 shares of BCRX stock, worth $216,206. This represents 0.01% of its overall portfolio holdings.

Number of Shares
27,790
Previous 28,240 1.59%
Holding current value
$216,206
Previous $174,000 21.26%
% of portfolio
0.01%
Previous 0.01%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

SELL
$6.41 - $8.69 $2,884 - $3,910
-450 Reduced 1.59%
27,790 $211,000
Q2 2024

Aug 13, 2024

SELL
$4.13 - $6.79 $1,239 - $2,037
-300 Reduced 1.05%
28,240 $174,000
Q4 2023

Feb 14, 2024

SELL
$4.98 - $6.77 $24,900 - $33,850
-5,000 Reduced 14.91%
28,540 $170,000
Q3 2023

Nov 13, 2023

SELL
$6.71 - $7.92 $33,550 - $39,600
-5,000 Reduced 12.97%
33,540 $237,000
Q2 2023

Aug 11, 2023

SELL
$6.96 - $8.81 $9,744 - $12,334
-1,400 Reduced 3.51%
38,540 $271,000
Q1 2023

May 15, 2023

BUY
$7.94 - $11.84 $1,111 - $1,657
140 Added 0.35%
39,940 $333,000
Q4 2022

Feb 13, 2023

BUY
$10.5 - $14.2 $7,875 - $10,650
750 Added 1.92%
39,800 $457,000
Q3 2022

Nov 14, 2022

SELL
$10.79 - $14.81 $58,265 - $79,974
-5,400 Reduced 12.15%
39,050 $492,000
Q2 2022

Aug 12, 2022

BUY
$7.89 - $17.88 $39,055 - $88,506
4,950 Added 12.53%
44,450 $470,000
Q1 2022

May 12, 2022

SELL
$11.56 - $19.76 $65,025 - $111,150
-5,625 Reduced 12.47%
39,500 $642,000
Q4 2021

Feb 14, 2022

BUY
$11.18 - $15.46 $40,807 - $56,429
3,650 Added 8.8%
45,125 $625,000
Q3 2021

Nov 12, 2021

BUY
$14.21 - $17.65 $217,057 - $269,603
15,275 Added 58.3%
41,475 $596,000
Q2 2021

Aug 13, 2021

BUY
$9.5 - $17.24 $76,000 - $137,920
8,000 Added 43.96%
26,200 $414,000
Q1 2021

May 18, 2021

BUY
$7.37 - $13.61 $134,134 - $247,702
18,200 New
18,200 $185,000

Others Institutions Holding BCRX

About BIOCRYST PHARMACEUTICALS INC


  • Ticker BCRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 185,944,992
  • Market Cap $1.45B
  • Description
  • BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat...
More about BCRX
Track This Portfolio

Track Visionary Wealth Advisors Portfolio

Follow Visionary Wealth Advisors and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Visionary Wealth Advisors, based on Form 13F filings with the SEC.

News

Stay updated on Visionary Wealth Advisors with notifications on news.